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Abstract
Introduction: Recent years have seen an increasing recognition of the need to improve access and retention in care for people
living with HIV/AIDS.This review aims to quantify patients along the continuum of care in sub-Saharan Africa and review possible
interventions.
Methods: We defined the different steps making up the care pathway and quantified losses at each step between acquisition of
HIV infection and retention in care on antiretroviral therapy (ART). We conducted a systematic review of data from studies
conducted in sub-Saharan Africa and published between 2000 and June 2011 for four of these steps and performed a meta-
analysis when indicated; existing data syntheses were used for the remaining two steps.
Results: The World Health Organization estimates that only 39% of HIV-positive individuals are aware of their status. Among
patients who know their HIV-positive status, just 57% (95% CI, 48 to 66%) completed assessment of ART eligibility. Of eight
studies using an ART eligibility threshold of5200 cells/mL, 41% of patients (95% CI, 27% to 55%) were eligible for treatment,
while of six studies using an ART eligibility threshold of5350 cells/mL, 57% of patients (95% CI, 50 to 63%) were eligible. Of
those not yet eligible for ART, the median proportion remaining in pre-ART care was 45%. Of eligible individuals, just 66% (95%
CI, 58 to 73%) started ART and the proportion remaining on therapy after three years has previously been estimated as 65%.
However, recent studies highlight that this is not a simple linear pathway, as patients cycle in and out of care. Published studies
of interventions have mainly focused on reducing losses at HIV testing and during ARTcare, whereas few have addressed linkage
and retention during the pre-ART period.
Conclusions: Losses occur throughout the care pathway, especially prior to ART initiation, and for some patients this is a
transient event, as they may re-engage in care at a later time. However, data regarding interventions to address this issue are
scarce. Research is urgently needed to identify effective solutions so that a far greater proportion of infected individuals can
benefit from long-term ART.
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Introduction
The success of antiretroviral therapy (ART) roll-out in sub-
Saharan Africa has been remarkable. Between 2004 and the
end of 2011, around 8 million people had initiated ART,
leading to dramatic reductions in HIV-associated morbidity
and mortality [1 3]. However, due to low HIV test uptake and
losses along the pathway between HIV testing and ART
treatment [4], only a minority of individuals in need of ART
are estimated to ever start treatment [5]. This is further
compounded by substantial additional losses that occur
during long-term treatment [6,7].
The essential steps in the HIVcare pathway for HIV-positive
individuals are HIV testing, assessment of eligibility for ART,
pre-ART care, initiation of ART and long-term retention on
ART. The importance of linkage and engagement in care
has received considerable attention in high-income countries
[8 10] where successes have resulted in improved health
outcomes for the patient [11,12] and reduced costs for the
healthcare system [13]. Characterization of losses along the
care pathway in high-income countries [13 15] has informed
the development of potential interventions [9]. However, the
scale of the challenge is so much greater in sub-Saharan Africa
where millions of patients are in need of life-long treat-
ment where healthcare systems are less well developed.
It is unclear whether interventions developed in high-income
countries will be feasible in this resource-constrained setting.
In the majority of sub-Saharan African countries, large
scale ART roll-out commenced in 2004 as treatment be-
came affordable and major donor-funding mechanisms
were established [16]. The rapid implementation of vertically
driven programmes was successful in providing life-saving
treatment for large numbers of patients in need. However,
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1this success was achieved with insufficient attention being
given to the establishment of the necessary linkages and
integration of HIV care within the broader health system.
These are essential for the establishment of an effective
continuum of care both before and during ART.
Engagement in HIVcare starts when an individual first tests
positive for HIV (Figure 1). This should be followed by
assessment for ART eligibility, which requires World Health
Organization (WHO) clinical staging and/or CD4 count testing.
CD4 count testing is a two-stage process, which requires that
a patient’s blood sample is obtained and sent for processing,
followed by the patient returning to receive his or her results
(typically 1 2 weeks later). Patients who meet the national
criteria for initiation of ART should commence ART without
undue delay whereas patients not yet eligible should be
retained in pre-ART care and undergo regular CD4 count
monitoring until the eligibility threshold is reached. Once
patients initiate ART, they should remain on uninterrupted
treatment for life. Losses occur at different steps along this
pathway, and may be temporary or permanent. The care
pathway is not a simple linear process and the dynamic
nature of linkage, retention, loss and re-engagement in care,
especially in the pre-ART stage, makes this a challenging
pathway to assess.
To date, the majority of studies from sub-Saharan Africa
have focused on treatment adherence and retention of
patients who have started ART [6,7,17 20]. However, much
more needs to be understood about the earlier components
of the care pathway. In addition, most studies have reported
on rates and risk factors for loss to care, with little focus on
potential interventions. In this article, we review the con-
tinuum of HIV care from infection to treatment, quantify
losses along the pathway in sub-Saharan Africa, and review
interventions to decrease attrition at different points in the
pathway.
Methods
Definitions
For the purpose of this review, we have divided the HIV care
pathway into (1) HIV testing; (2) pre-ART care comprising
assessment of ART eligibility, retention in pre-ART care prior
to ART eligibility, initiation of ART; and (3) retention in ART
care (Figure 1). Where available, we used synthesized data
from published systematic reviews or from WHO reports.
Where such data were either unavailable or a more com-
prehensive review was possible, we conducted systematic
literature reviews and data syntheses. Possible interven-
tions and operational solutions aimed to reduce losses at
each stage of the pathway are subsequently reviewed and
discussed.
Eligibility criteria and search strategy
We sought studies investigating retention in care in the pre-
ART period, and linkage to care at three steps: ART eligibility
assessment, pre-ART care and ART initiation. Studies were
omitted if they were carried out in the private health-
care sector, if they reported unsystematic observations (case
reports and case series), or if they were secondary data
sources (editorials and viewpoints).
Primary outcomes were the proportion of individuals
completing ART assessment, retained in pre-ART care and
initiating ART as defined by the authors of the study.
We searched Medline, Embase and Global Health for
studies reporting retention between HIV testing and ART
using a compound search strategy. Bibliographies of retrieved
articles were searched for additional studies. Our search
was limited to studies conducted in sub-Saharan Africa
Boxes within the grey arrow show the steps in the pathway of HIV care: HIV testing, assessment for ART eligibility,
ART initiation, retention in pre-ART care until eligible, continuous lifelong ART. The dotted line and circle outside the
grey arrow show the process of defaulting and re-engaging in care.
HIV
test
Continuous
lifelong ART Assessment for
ART eligibility:
￿ Clinical staging
￿ CD4 count
ART
initiation
Retention in pre-
ART care until
eligible Not yet eligible
Eligible
HIV
infection
HIV
testing
Pre-ART care ART care
Not in
care
Not in
care
Figure 1. The care pathway for HIV positive individuals.
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2published between 2000 and June 2011. In addition, we
searched for conference abstracts from all conferences of the
International AIDS Society (2000 2010), and all Conference
on Retroviruses and Opportunistic Infections (2000 2010).
No language restriction was applied.
Studies were entered into an electronic database (EndNote
X1) to screen potentially eligible studies by title and abstract.
Articles were screened by title, then by abstract, indepen-
dently, and in duplicate (GD, KK). Data was extracted in
duplicate (GD, KK) using a standard data extraction form.
Data analysis
We calculated point estimates and 95% confidence inter-
vals (CIs) for the proportion of patients linking to care at
various stages of the care pathway. The variance of the
raw proportions was stabilized using a Freeman-Tukey type
arcsine square-root transformation, and estimates were
pooled using a DerSimonian-Laird random effects model.
Between study heterogeneity was assessed with the t
2
statistic (on the transformed scale), and subgroup analyses
were run to compare studies that used a time cut-off for
determining linkage with those that did not. All p values
were two-sided, and a p value of B0.05 was considered
significant. Analyses were conducted using Stata (version 11,
www.stata.com).
Results
Out of 755 potentially eligible studies, 37 were retained
for analysis (Figure 2). Study characteristics are summarized
according to the different steps in the pathway (Tables 1 4).
HIV testing
The proportion of HIV-positive individuals in sub-Saharan
Africa whose infection remains undiagnosed is often derived
from population-based surveys in which participants are
asked to provide details about previous HIV testing. However,
a considerable proportion of those who report a previous
negative test may have since seroconverted.Thus, the overall
median estimate of 39% of people living with HIV in sub-
Saharan Africa knowing their correct HIV status may be an
overestimate [5]. This is suggested by some country-level
studies. For example, the Kenya AIDS Indicator Survey linked
HIV test results to perceived HIV status [60]. This revealed
that among HIV-positive individuals, 56% reported they did
not know their status, 28% mistakenly thought they were
HIV-negative and only 16% actually knew their HIV-positive
status [60]. Similarly, in a peri-urban South African commu-
nity with high HIV prevalence, the prevalence of previously
undiagnosed HIV was 46% despite coverage of HIV testing
being high (71%) [61].
Pre-ART care
Assessment of ART eligibility
For individuals who test positive for HIV infection, the next
key step in the care pathway is assessment of ARTeligibility -
a process that might be regarded as indicative of an initial
link to care. Of the 22 published studies we identified as
eligible for inclusion (Table 1), the majority were conducted
in South Africa (n 9). Eleven studies reported the propor-
tions of patients enrolling in care post-diagnosis. Two studies
were excluded because they were unrepresentative of the
general population accessing clinics and hospitals: one was
conducted in a mobile clinic [34] and among female sex
workers in Rwanda [28].
The proportion of patients assessed for ART eligibility
(reflecting linkage to care) ranged from 42% (95% CI, 39% to
46%) to 70% (95% CI, 68% to 72%), with an overall pooled
estimate of 57% (95% CI, 48% to 66%; t
2 0.07). In eight out of
the eleven studies, ART eligibility was assessed by CD4 cell
count measurement and the proportions of patients in which
this was successfully performed ranged from 55% (95% CI,
51% to 60%) to 86% (95% CI, 77% to 94%) with a pooled
proportion of 66% (95% CI, 54% to 78%; t
2 0.14). However,
only five of these studies reported the number of patients
who returned for their test result, with proportions ranging
from 30% (95% CI, 26% to 34%) to 88% (95% CI, 87% to 89%)
and a pooled estimate of 51% (95% CI, 25% to 78%; t
2 0.40).
This pooled estimate is similar to the finding of an earlier
systematic review in which a median proportion of 59%
completed ART eligibility assessment [4].
Proportion of individuals eligible for ART
We next assessed the proportion of individuals with newly
diagnosed HIV infection who were assessed and found to be
eligible for ARTaccording to national ARTguidelines currently
in use at the time of the study. We identified 16 studies
eligible for inclusion (Table 2) of which seven were from
South Africa. Ten studies reported on the proportions of
patients who were eligible for ART based on a CD4 count
threshold of 5200 cells/mL, but two were excluded for
reasons of non-generalizability [28,45]. The proportion found
to be eligible at this CD4 count threshold ranged from
21% (95% CI, 20% to 22%) to 59% (95% CI, 59% to 60%) with
a pooled proportion of 41% (95% CI, 27% to 55%; t
2 0.15).
61 studies selected for full text review (48 articles + 13 abstracts)
- 169 duplicates
- 523 irrelevant on basis
  of title and/or abstract
- 2 conference abstracts-
  retrieved the published
  paper
- 14 ineligible articles
- 10 poor quality studies 
37 publications retained for analysis (31 articles and 6 abstracts)
Screen 1: 694 excluded 
Screen 2: 24 excluded
755 potentially eligible citations identified for
screening
  -  734 potentially relevant citations obtained from keyword 
        searches on electronic databases 
  -  6 potentially relevant citations retrieved from reference lists
  -  15 potentially relevant citations gathered from conference
     abstracts 
Figure 2. Study selection process.
Kranzer K et al. Journal of the International AIDS Society 2012, 15:17383
http://www.jiasociety.org/index.php/jias/article/view/17383 | http://dx.doi.org/10.7448/IAS.15.2.17383
3Table 1. Proportion of patients with newly diagnosed HIV infection who complete assessment of eligibility for antiretroviral therapy
Author Country Setting
Year of
the
study N
Enrolled into HIV care
as a prerequisite of
accessing CD4 counts
(time cut-off)
Blood sample for CD4
count provided
(time cut-off)
Returned for CD4 results
(time cut-off)
Enrolled in HIV care
(time cut-off)
Assefa [21] Ethiopia Public sector sites 2008 1314 47% (immediately after
testing)
Assefa [21] Ethiopia Mobile HIV testing service for high
risk individuals
2008 2035 26% (two months)
Mulissa [22] Ethiopia Urban, hospital 2003 08 2191 70% (no time cut-off, but 49%
enrolled the same day)
Amolloh [23] Kenya Asembo, home-based testing service 2008 09 737 42% (two to four months)
Waxman [24] Kenya Eldoret, emergency department,
hospital
2006 61 87% (no time cut-off)
Gareta [25] Malawi Lilongwe, hospital, pregnant women 2006 08 478 55% (no time cut-off)
Tayler Smith [26] Malawi Thylo, district hospital, patients with
clinical stage I or II
2008 09 1428 45% (at least one month
follow-up)
Micek [27] Mozambique Urban, HIV testing services 2004 05 7005 57% (30 days) 77% (30 days)
Braunstein [28] Rwanda Kigali, female sex workers 2007 08 141 85% (no time cut off)
April [29] SA Cape Town, hospital, primary care
clinic
2006 375 62% (six months)
Kranzer [30] SA Cape Town, hospital, primary care
clinic
2004 09 988 63% (six months)
Larson [31] SA Johannesburg, hospital, clinic 2008 09 416 85% (12 weeks) 35% (12 weeks)
Losina [32] SA Durban, semi-private hospital 2006 07 454 55% (eight weeks) 85% (eight weeks)
Naidoo [33] SA Johannesburg, clinic 225 47% (one week)
Govindasamy
[34]
SA Cape Town, mobile HIV testing
service
2008 09 192 73% (no time cut off) 42% (no time cut off) of those
who received their CD4 result
Bassett [35] SA Durban, semi-private hospital 2006 08 1474 69% (90 days)
Ingle [36] SA Free State, public sector clinics 2004 07 44844 74% (no time cut-off)
Luseno [37] SA Community-based trial 199 46% (no time cut off)
Nsigaye [38] Tanzania Clinic 2005 08 349 68% (no time cut-off)
Amuron [39] Uganda Jinja, clinic 2004 06 2483 88% (no time cut-off)
Wanyenze [40] Uganda Kampala, hospital 2004 05 142 56% (six months)
Nakigozi [41] Uganda Rakai community cohort study 1145 69% (six months)
Wanyenze [42] Uganda Kampala, hospital 2004 211 48% (three months),
57% (six months)
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4Table 2. Proportion of individuals with new HIV diagnoses who are eligible for antiretroviral therapy
Author Time Country Site N CD4B200 CD4B350 Stage 3 Stage 4 Eligible Eligibility criteria
Mulissa [22] 2003 08 Ethiopia Clinic 2191 49% 13.3%
Mcgrath [43] 2005 06 Malawi Hospital 730 87% Stage 3 or 4
Micek [27] 2004 05 Mozambique Clinic 3046 49% CD4B200 or stage 4, CD4 200 to 350 or
stage 3 and pregnant
Nakanjako [44] 2004 Nigeria Emergency department 111 49% 22.0%
Braunstein [28] 2006 07 Rwanda FSW 192 11% 43%
Kranzer [30] 2004 09 SA Primary care clinic, hospital 112 34% 60%
van Schaik [45] 2008 09 SA Mobile clinic 65 11% 25%
Basset [35] 2006 08 SA Semi-private hospital 1012 53%
Ingle [36] 2004 07 SA Public clinics, hospitals 33182 57% (04)
a
54% (05/6)
67% (07)
Lessels [46] 2007 SA Clinic 7655 41% 62%
Losina [32] 2006 07 SA Semi-private hospital 248 53%
April [29] 2006 SA Primary care clinic, hospital 375 31% 31%
Nunu [47] 2009 Swaziland Hospital 637 57% Not stated
Konde-Lule [48] Uganda Public clinics, hospitals 203 36% 57%
Amuron [39] 2004 06 Uganda Clinic 4321 58% CD4B200 or WHO Stage 4
Carter [49] 2003 08 Multisite ANC, post pregnancy 6036 21% 45% 10% 1%
aProportions were calculated on the basis of calendar years
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5Six studies also reported on the proportions eligible using
a CD4 count threshold of 5350 cells/mL, with proportions
ranging from 45% (95% CI, 44% to 47%) to 62% (95% CI, 61%
to 63%) and a pooled estimate of 57% (95% CI, 50% to 63; t
2
0.13). Six studies reported on the proportions of patients
who were eligible for ART based on clinical criteria (WHO
clinical Stage 3 and 4). Proportions ranged from 49% (95% CI,
48% to 51%) to 87% (95% CI, 84% to 89%) with a pooled
proportion of 64% (95% CI, 53% to 74%; t
2 0.13).
Pre-ART care prior to ART eligibility
We identified only five studies reporting on retention in care
of individuals not yet eligible for ART; four of these were from
South Africa (Table 3). The duration of pre-ART care assessed
was highly variable between these studies [30,36,46,50].
No study reported the proportion retained in care on
becoming eligible for ART. Retention in pre-ART care in
South Africa ranged from 41% to 46% [30,36,46,50]. The
remaining study from Malawi estimated retention in pre-
ART care to be 59% [51]. The median proportion retained in
pre-ART care was 45%. As few studies were identified, all
with considerable heterogeneity regarding time-cut offs, a
pooled estimate was not calculated. Two of the five studies
did not specify any time-cut off [30,51], while the other three
studies assessed repeat CD4 count measurements or visits *
six to twelve months after the initial eligibility assessment
[36,46,50].
Initiation of ART
We identified 19 studies that reported the proportions of
ART-eligible individuals who started ART (‘‘linkage to ART’’)
(Table 4). Ten studies in seven sites were conducted in South
Africa with the remainder conducted in Kenya (n 1),
Malawi (n 4), Mozambique (n 1), Swaziland (n 1) and
Uganda (n 2). A study reporting linkage amongst TB,
co-infected patients was excluded from the meta-analysis
as these patients have an unrepresentative high mortality
risk [53]. In the remaining 18 studies, the proportion linking
to ART ranged from 31% (95% CI, 29% to 33%) to 86% (95%
CI, 83% to 89%), with an overall pooled proportion of 66%
(95% CI, 58% to 73%; t
2 0.12). An earlier review of 14 studies
found the median proportion of individuals initiating ART was
68% [4]. Eight of the studies included in our meta-analysis did
not specify the time period within which patients could link
to ART care. However, in a subgroup analysis there was no
difference in the proportion linking to ART care comparing
studies that used a time cut-off for determining a link with
those that did not (p 0.24). Studies which reported on time
between HIV testing or staging and initiation of ART showed
that the majority of patients started treatment within one
month; however, two studies reported median delays of
between 2.4 and 6.6 months [27,35].
Eight studies assessed the contribution of mortality as
a potential cause for not starting ART and reported a
median mortality of 5.5% (interquartile range 4.5% to
12%) among eligible patients waiting to start treatment
[17,35,36,39,43,54,56]. In these studies, it is difficult to
ascertain whether death is the cause or the result of not
starting ART. Some studies traced individuals who were
thought to have not started ART [39,54]; between 3% and
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6Table 4. Proportions of HIV-positive individuals assessed as eligible for antiretroviral therapy who start treatment
Author Country Setting
Year of
the study N
Linkage to ART care for
those eligible
(time cut-off)
Median (mean)
time to ART
initiation Comment
Karcher [17] Kenya Nyanza, district hospital 2004 05 159 78% (no time cut-off) 3% died, 13% denied treatment
Tayler-Smith [52] Kenya Kibera slum, clinics 2005 08 2471 82% (one month)
Tayler-Smith [26] Malawi Thyolo, district hospital, patients with
WHO Stage 1/2 and CD4B250 cells/mL
2008 09 681 64% (six months) 33 days (21 44)
Gareta [25] Malawi Lilongwe, hospital, pregnant women 2006 08 222 69% (four weeks)
Zachariah [53] Malawi Thyolo, district hospital, TB patients 2003 04 742 14% (no time cut-off)
Mcgrath [43] Malawi Karonga rural, district hospital 2005 06 659 86% (no time cut-off) 22 days (13 27) 5% died, 0.5% had moved, 3% alive not
taking ART, 5% untraceable
Micek [27] Mozambique Urban, HIV testing services 2004 05 1506 31% (90 days) 71 days
Kranzer [30] SA Cape Town, hospital, primary care clinic 2004 09 219* 67% (within six months)
Ingle [36] SA Free State, public sector clinics, eligible
at first CD4 measurement
2004 07 19089 59% (no time cut-off) 95 days (53 170) 25% died, 3% in care, 13% not in care
Ingle [36] SA Free State, public sector clinics, eligible
at subsequent CD4 measurement
2004 07 2994 58% (no time cut-off) 13% died, 19% in care, 9% not in care
April [29] SA Cape Town, hospital, primary care clinic 2006 72 68% (no time cut-off)
Bassett [54] SA Durban, semi-private hospital 2006 501 81% (three months) 6% died, 3% accessed a different service,
0.6% moved away, 0.6% promised to return,
7% were untraceable
Bassett [35] SA Durban, semi-private hospital 2006 08 538 39% (12 months) 6.6 months 17% died
Kaplan [55] SA Cape Town, primary care clinic, women 2002 07 2131 81% (no time cut-off) 4% died, 7% loss to follow-up
Lawn [56] SA Cape Town, primary care clinic 2002 05 1235 75% (no time cut-off) 34 days (28 50) 5% died, 9% preparing for ART, 11% loss to
follow-up
Feucht [57] SA Pretoria, hospital, children 2004 243 40% (no time cut-off)
Geng [58] SA Mbarara, clinic 2009 10 697 58% (three months)
Nunu [47] Swaziland Hospital 2009 363 58% (on the assigned date)
Amuron [39] Uganda Jinja, clinic 2004 06 2182 85% (no time cut-off) 33 days (15 406) Survival status was investigated for all losses
between testing and treatment (included
losses of patients not returning for their CD4
result): 7% died, 8% on ART with a different
provider, 6% were alive and not on ART, 4%
untraceable
Parkes [59] Uganda NGOs and governmental health units 2004 06 458 61% (three months)
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719% of such patients were either retained in care in the
same clinical service or had accessed treatment elsewhere.
ART care
Patients receiving ART may leave clinical care for three
reasons: death, transfer of care to another service (transfer-
out) and loss to follow-up. Losses during ARTare much better
documented than those occurring earlier in the care path-
way. Early mortality is typically high in programmes in sub-
Saharan Africa [62]. Systematic reviews have estimated that
death accounted for around 40% of patient attrition during
the first two to three years of treatment [6,7]. Key
risk factors for this include a low baseline CD4 count and
advanced WHO stage of disease [63]. Thus, interventions
upstream in the care pathway are needed to prevent late
presentation. Long-term mortality risk decreases substan-
tially [63 66], especially once a CD4 cell count threshold of
200 cells/mL has been exceeded [67].
Early in the scale-up of ART in sub-Saharan Africa,
treatment sites were few; patients were typically severely
immunocompromised at the time of ART initiation; and
prognosis was uncertain. Thus, transfer of patient care
between ART clinics was relatively uncommon. However,
over time the number of decentralized treatment sites has
expanded; patients are generally less immunocompromised
when commencing ART; and patient confidence in ART has
grown [65]. These factors may explain why in some settings,
rates of transfer between services have risen steeply [64,68].
Data on true outcomes of patients transferred from one
program to another are scarce [69,70], but if transfer of care
is successful, then the patient is effectively retained in care.
A challenge to rapidly expanding ART programmes in sub-
Saharan Africa is the issue of preventing ‘‘losses to follow-
up.’’ Patients are usually classified as ‘‘lost to follow-up’’ if
they fail to attend follow-up appointments over a specified
duration without having been actively transferred to another
ART clinic, and if they are not known to have died. A
systematic review of 39 ART cohorts in sub-Saharan Africa
reported an average retention of 65% at three years [6]. In
recent years, many ARTcohorts have rapidly increased in size
with disproportionate increases in the number of patients
compared to the number of healthcare workers. Losses to
follow-up have reportedly grown over successive calendar
periods, indicating a growing problem with long-term reten-
tion in care [64,65,71].
Defining a patient as ‘‘lost to follow-up’’ is often based on
exclusion of other known reasons for failure of the patient to
attend. However, this may conceal considerable unascer-
tained mortality. A systematic review summarizing studies
that traced individuals lost to follow-up showed that on
average 40% of such individuals had actually died [72]. A
study from South Africa reported that 78% of such deaths
occurred within the first three months after their last clinic
visit [71], suggesting these deaths were the reason and not
the result of being lost to follow-up.
Another complexity in reporting rates of loss to follow-up
is that patients may cycle in and out of care. Thus, patients
who fulfil the widely used definition of loss to follow-up at
Individuals living with HIV 
in the community
Individuals eligible for ART
Individuals knowing their
serostatus
Individuals completing
assessment  for ART eligibility
Individuals not yet eligible for ART
Individuals retained in pre-ART care
39%
57%
50% 50%
66% 45%
Individuals initiating ART
Individuals retained on ART
65%
Figure 3. Cumulative losses along the HIV care pathway as reported by cross-sectional studies addressing each step in the pathway.
The proportions (%) shown indicate the proportions of individuals who successfully complete each step in the pathway.
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8Table 5. Interventions to increase HIV diagnosis and engagement of patients in pre-ART HIV care and to reduce losses to follow-up throughout the care pathway
Step Targeting Intervention/operational solution Evidence
HIV testing capacity
m Integration of HIV testing into other healthcare services
m Testing by lay healthcare workers
m Decentralization of testing
m Self-testing
m Observational studies [75,76]
m Observational studies [77 79]
m Feasibility study [80]
HIV testing
Demand for HIV testing
m Targeted testing in high risk groups
m Home-based and community-based testing, mobile services
m Provider-initiated testing
m Workplace testing
m Incentivized testing
m Self-testing
m Observational studies [81,82]
m RCT [83], observational studies [84 87,93]
m Observational studies [89 91]
m RCT [87]
m RCT [93,94]
m Feasibility study [80]
Completion of staging and
linkage to pre-ART and ART care
m Point of Care CD4 count testing
m Decentralization
m Integration into existing services/primary healthcare
m Support tools (e.g. cell phone messages, patient held appointment
cards)
m Observational studies [95,96]
m Observational study [38]
m Observational study [38]
Pre-ART care
Retention in pre-ART care prior
to ART eligibility
m Efficient referral service
m Transport allowance
m Adherence counselling
m Regular visits (e.g. Cotrimoxazole prophylaxis)
m Decentralization
m Integration into existing services/primary healthcare
m Task shifting
m Earlier initiation
m Observational study [97]
m Home-delivered ART
m Community ART
m Targeted adherence counselling
m Drugs with less toxicity, side effects and easier schedule
m Task shifting
m Decentralization
m RCT [98]
m Observational study [99,100]
m Observational studies [101,102]
m Some evidence from resource rich settings[103]
m RCT[104], observational studies [102,105 109]
m Observational study [77,106,108 113]
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9one time point might re-engage with care at a later stage
and thus cease to be lost to follow-up. A systematic review
of this issue conducted in 2011 identified nine studies from
sub-Saharan Africa and found that an average of 12% of
individuals on ART had previously interrupted but subse-
quently restarted treatment [73].
Cumulative losses along the pathway
No study has yet measured the cumulative losses occurring
along the entire care pathway. This would require long-
term prospective demographic surveillance, although such a
process in itself would likely alter the outcomes of interest.
An alternative approach is to combine pooled estimates of
losses from each of the steps in the care pathway that we
have described. However, using data in this way from cross-
sectional studies with typically short duration of follow-up
is methodologically flawed [4]. A critical issue is that the
care pathway is not a simple linear process and patients
clearly cycle in and out of care; a patient who fails to
complete one step in the pathway may re-engage with
the treatment pathway at a later time-point and ultimately
receive successful long-term ART. Thus, use of the individual
estimates of the losses described thus far and summarized in
Figure 3 might erroneously lead to the conclusion that of all
HIV-positive individuals in the community, only 7% (0.39 
0.57 0.50 0.66) would start ART and 5% (0.039 
0.57 0.50 0.45) would be retained in pre-ART care for
some duration.
The assertion that these are likely to be underestimates of
the true proportions receiving care is supported by detailed
datafrom a high HIVprevalence community in South Africa. In
a population-based sero-prevalence survey, 54% of all HIV-
positive individuals knew their positive HIV sero-status [61].
A study of this community from the same period showed
that 63% of HIV-positive individuals were assessed for ART
eligibility within six months of diagnosis, 26% were eligible for
ARTand 66% started ART within six months of diagnosis [30].
Combining these estimates of losses along the HIV care
pathway in this community would lead to an estimated ART
coverage in the community of 6% (0.54 0.63 0.26 0.66),
whereas in reality a population-based survey reported
a coverage of 33.5%, which is more than five-fold higher
[61]. This illustrates the complexities involved in studying
the HIV care pathway and the need for better means of
assessment.
Interventions
Multiple interventions are needed to address high rates of
patient attrition at every stage of the HIV care pathway.
Strategies to reduce deaths among patients who have started
ART have been described elsewhere [74], so instead, we
should focus on strategies to increase HIV diagnosis and
engagement of patients in pre-ART care and aim to reduce
losses to follow-up throughout the pathway.
Interventions either aim to increase the efficiency and
capacity of services, or accessibility and acceptability of these
services (Table 5). Interventions to increase HIV testing
include task-shifting (testing through lay healthcare workers)
[77 79] and provider-initiated testing [89 91] as well as
mobile, community, home-based and workplace services
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10[83 87,92] which bring the service nearer to the patient and
thus increase accessibility, which might in turn increase
acceptability. Other interventions aimed to increase accept-
ability of testing are self-testing [80] and incentivized test-
ing [93,94]. More recently, community-based strategies
for HIV testing and ART delivery have been developed
[84,88,99] as a way to further expand access to care. By
virtue of being placed in the community, these strategies
are decentralized and use task-shifting to engage lesser
trained health staff, and thus might be more cost-effective
[125].
Only four studies have assessed interventions aimed at
reducing losses in the pre-ART period. These have examined
point-of-care CD4 count testing [95,96], more efficient
referral systems [38], transport vouchers [38] and regular
visits to refill trimethoprim-sulphmethoxazole prophylaxis
[97]. In contrast, many studies have reported on interven-
tions to reduce loss to follow-up of patients on ART [126].
Some of these interventions are structural such as task-
shifting [104 108], decentralization [77,106,108 111], inte-
gration [114,115] and continuous drug supply [118,119],
whereas others are aimed at the individual such as
adherence counselling [101,102] and transport reimburse-
ment [118,120,121].
Few interventions have been assessed for their efficacy
and cost-effectiveness in randomized controlled trials
[83,92,94,104,116], and most observational studies have
assessed feasibility rather than effectiveness [80,114,123].
Evidence for a positive effect of, for example, transport
vouchers and secured drug supplies comes mainly from
risk factor analysis and semi-qualitative studies [118 121].
Some interventions have only been assessed for one specific
step in the pathway, but not for others. An example is
adherence counselling, which has been shown to have some
effect on retention in ART care [101,102], but the effect
of counselling on retention in pre-ART care or on linkage to
ART care has not yet been formally assessed.
Integration of care has mainly concentrated on tubercu-
losis and PMTCT programs [115,127] or the beneficial effects
derived by other health services through the integration
of HIV care [128]. The lack of a common conceptual frame-
work on what integration means has impeded more rigorous
evaluation of the impact of integration on retention and
testing [129]. One study conducted in nine countries in sub-
Saharan Africa, found that providing ART in an integrated
approach resulted in substantially less defaulting from care
compared to vertical ART delivery [130]. As HIV is a chronic
disease, integration is important not only to improve reten-
tion, but also to provide comprehensive care (Table 6). This
has been conceptualized in the WHO’s Integrated Manage-
ment of Adolescent and Adult Illness programme [131].
Conclusions
Substantial losses occur at every stage of the HIV care
pathway for HIV-positive individuals in sub-Saharan Africa.
Assessment of these losses is complex as is engagement in
care; loss to care and return to care is a dynamic, non-linear
and time-dependent process. To date, no study has yet
defined the cumulative losses throughout the pathway. Data
regarding interventions to address these losses are scarce,
especially with regards to the care pathway prior to ART
initiation. Research is urgently needed to identify effective
solutions so that a far greater proportion of HIV-positive
individuals can reap the benefits of ART. Such research
should take into account the important gender differences
that are becoming increasingly apparent with respect to
accessing testing [132] and treatment and care [133].
The ‘‘test and treat’’approach to reducing HIV transmission
proposes that very high coverage of HIV testing and
immediate initiation of ART regardless of the stage of HIV
progression would substantially reduce HIV transmission
[134], and has been met with considerable enthusiasm.
The data in this review serve as a reminder of the huge
operational challenges that will be faced in implementing
such a strategy. Considerable investment and energy must be
devoted to identifying effective interventions to strengthen
the care pathway, thereby permitting more effective im-
plementation of current policy. As the care pathway is
strengthened, ‘‘test and treat’’ will become a more viable
strategy.
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Table 6. Comprehensive HIV care
Prevention
Trimethoprim-sulphamethoxazole prophylaxis
Isoniazid preventive therapy
Intensified tuberculosis case finding
Cryptococcal antigen screening
Cervical cancer screening
Prevention of mother to child transmission
Prevention of transmission to sexual partners
Acute services
Tuberculosis
Mental health
Sexual transmitted diseases
Antenatal care
Family planning
Chronic services
Mental health
Chronic disease (e.g. diabetes, ophthalmological services, etc.)
Care of the elderly services
Social support
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